Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ABBV-105, upadacitinib, and ABBV-599 in moderately to severely active systemic lupus erythematosus
NL-OMON49791Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elsubrutinib, upadacitinib and ABBV-599 in systemic lupus erythematosus (SLE) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Primary efficacy endpoint. Started Feb 2020; status: completed.
02
Drugs
elsubrutinibupadacitinibABBV-599
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON49791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49791.